FDA
-
-
-
-
-
-
-
Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment
-
-
-
-
-
-
-
Moleculin presents cardiac safety data for Annamycin at 2026 ASCO meeting
-
-
-
-
-
-
-
Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits
-
-
-
-
-
-
-
Moleculin highlights Annamycin's non-cardiotoxic profile in CEO segment
-
-
-
-
-
-
-
Moleculin to Present at 38th Annual ROTH Conference
-
-
-
-
-
-
-
Moleculin receives Japanese patent allowance for Annamycin formulation
-
-
-
-
-
-
-
Moleculin expects first pivotal trial data readout in Q1 2026
-
327,059 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

